While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
AI-enabled wearable remote patient monitoring platform successfully completed pilot deployments in a government super-specialty hospital and emergency ambulances
Seasoned HR leader brings over 15 years of experience in global talent strategy, organizational transformation, and workforce planning
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
Vijay brings more than 28 years of experience across healthcare, technology, edtech, manufacturing, and global business environments
World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
Subscribe To Our Newsletter & Stay Updated
